OBJECTIVE: To compare the safety and efficacy of enoxaparin and unfractionated heparin in the treatment of @entity1151 ( @entity1151 ). MATERIAL AND METHODS: Fifty-six @entity1 with @entity1151 who did not need fibrinolytic treatment were enrolled prospectively. The @entity1 were randomly assigned to 2 treatment groups: Group A received @entity2120 (1 mg/kg every 12 hours) and Group B received adjusted doses of unfractionated heparin. The oral anticoagulant therapy was started on confirmation of the diagnosis and continued for 6 months. Incidences of recurrence of @entity1031 and of severe @entity548 were assessed at the end of this period. RESULTS: Six @entity1 were withdrawn from the study. Twenty-nine of the 50 remaining @entity1 were in Group A (enoxaparin) and 21 in Group B (unfractionated heparin). A recurrence of @entity1031 was diagnosed in 3 @entity1 from Group A (10.7%) and 2 @entity1 from Group B (9.5%). There were no significant differences. Two @entity1 died, one @entity204 being attributed to @entity548 secondary to the oral anticoagulant treatment (Group A) and the other to a process unrelated to @entity1151 . CONCLUSIONS: Enoxaparin seems to be as effective and safe as unfractionated heparin in the initial treatment of @entity1151 .

[Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['submassive pulmonary thromboembolism', 'PTE'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity2120 :: ('MESH:D017984', 'Chemical') :: ['enoxaparin']
@entity1151 :: (MESH:D011655,Disease) :: ['submassive pulmonary thromboembolism']
